Weight loss in Huntington disease increases with higher CAG repeat number

被引:182
作者
Aziz, N. A. [1 ]
van der Burg, J. M. M. [3 ]
Landwehrmeyer, G. B. [4 ]
Brundin, P. [3 ]
Stijnen, T. [2 ]
Roos, R. A. C. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands
[3] Lund Univ, Wallenberg Neurosci Ctr, Dept Expt Med Sci, Neuronal Survival Unit, S-22100 Lund, Sweden
[4] Univ Ulm, Dept Neurol, D-7900 Ulm, Germany
关键词
D O I
10.1212/01.wnl.0000334276.09729.0e
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded number of CAG repeats in the huntingtin gene. A hallmark of HD is unintended weight loss, the cause of which is unknown. In order to elucidate the underlying mechanisms of weight loss in HD, we studied its relation to other disease characteristics including motor, cognitive, and behavioral disturbances and CAG repeat number. Methods: In 517 patients with early stage HD, we applied mixed-effects model analyses to correlate weight changes over 3 years to CAG repeat number and various components of the Unified Huntington's Disease Rating Scale (UHDRS). We also assessed the relation between CAG repeat number and body weight and caloric intake in the R6/2 mouse model of HD. Results: In patients with HD, mean body mass index decreased with -0.15 units per year (p < 0.001). However, no single UHDRS component, including motor, cognitive, and behavioral scores, was independently associated with the rate of weight loss. Patients with HD with a higher CAG repeat number had a faster rate of weight loss. Similarly, R6/2 mice with a larger CAG repeat length had a lower body weight, whereas caloric intake increased with larger CAG repeat length. Conclusions: Weight loss in Huntington disease (HD) is directly linked to CAG repeat length and is likely to result from a hypermetabolic state. Other signs and symptoms of HD are unlikely to contribute to weight loss in early disease stages. Elucidation of the responsible mechanisms could lead to effective energy-based therapeutics. Neurology (R) 2008;71:1506-1513
引用
收藏
页码:1506 / 1513
页数:8
相关论文
共 41 条
[1]   THE RELATIONSHIP BETWEEN TRINUCLEOTIDE (CAG) REPEAT LENGTH AND CLINICAL-FEATURES OF HUNTINGTONS-DISEASE [J].
ANDREW, SE ;
GOLDBERG, YP ;
KREMER, B ;
TELENIUS, H ;
THEILMANN, J ;
ADAM, S ;
STARR, E ;
SQUITIERI, F ;
LIN, BY ;
KALCHMAN, MA ;
GRAHAM, RK ;
HAYDEN, MR .
NATURE GENETICS, 1993, 4 (04) :398-403
[2]   Hypocretin and melanin-concentrating hormone in patients with Huntington disease [J].
Aziz, Ahmad ;
Fronczek, Rolf ;
Maat-Schieman, Marion ;
Unmehopa, Unga ;
Roelandse, Freek ;
Overeem, Sebastiaan ;
van Duinen, Sjoerd ;
Lammers, Gert-Jan ;
Swaab, Dick ;
Roos, Raymund .
BRAIN PATHOLOGY, 2008, 18 (04) :474-483
[3]  
Aziz NA, 2007, REV NEUROSCIENCE, V18, P223
[4]   Weight loss in early stage of Huntington's disease [J].
Djoussé, L ;
Knowlton, B ;
Cupples, LA ;
Marder, K ;
Shoulson, I ;
Myers, RH .
NEUROLOGY, 2002, 59 (09) :1325-1330
[5]   AN ANTHROPOMETRIC ASSESSMENT OF HUNTINGTONS-DISEASE PATIENTS AND FAMILIES [J].
FARRER, LA ;
MEANEY, FJ .
AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY, 1985, 67 (03) :185-194
[6]  
Fitzmaurice GM., 2004, APPL LONGITUDINAL AN
[7]  
Gaba AM, 2005, AM J CLIN NUTR, V81, P1335
[8]   The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study [J].
Goodman, Anna O. G. ;
Murgatroyd, Peter. R. ;
Medina-Gomez, Gema ;
Wood, Nigel I. ;
Finer, Nicholas ;
Vidal-Puig, Antonio J. ;
Morton, A. Jennifer ;
Barker, Roger A. .
EXPERIMENTAL NEUROLOGY, 2008, 210 (02) :691-698
[9]   Rate and correlates of weight change in Huntington's disease [J].
Hamilton, JM ;
Wolfson, T ;
Peavy, GM ;
Jacobson, MW ;
Corey-Bloom, J .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (02) :209-212
[10]  
Harper P.S., 1996, HUNTINGTONS DIS